Skip to content

Ayurvedic management of Asrugdara (Abnormal Uterine Bleeding) in Perimenopausal Women

Efficacy of Nyagrodhadi Ghanavati with and without Panchatikta Ghrita Matra Basti in the management of Asrugdara w.s.r. to Endometrial Hyperplasia in Perimenopausal women -an open labelled randomized comparative clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/111063
Enrollment
20
Registered
2026-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N93- Other abnormal uterine and vaginalbleeding

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Married female having chief complaint of regular/irregular menstrual cycle with bleeding more than 7days and/or PBAC Score more than 100 . 2.On USG (TVS), Endometrial thickness (ET): The cut-off values for perimenopausal symptomatic women will be ET (endometrial thickness) more than and equal to 8 mm on 8th to 11th day of menstrual cycle.

Exclusion criteria

Exclusion criteria: 1.Women with Hb less than 8gm percentage. 2.K/C/O of bleeding disorders like Hemophilia, Von Willebrand disease, Thrombocytopenia. 3.Congenital anomaly of reproductive tract. 4.Known patients of cervical polyp, endometriosis, adenomyosis, ovarian cyst, pelvic inflammatory diseases, submucous or intramural fibroid more than 5cm and endometrial malignancy. 5. Suffering from chronic systemic diseases like, uncontrolled hypertension (Systolic blood pressure above 160 & Diastolic blood pressure above 100mmhg), uncontrolled diabetes (above the range of 160-200 mg/dl (RBS). 6.Patient not willing to participate.

Design outcomes

Primary

MeasureTime frame
Primary outcome: 1.Reduction in the amount and duration of menstrual blood loss. 2.Reduction in the endometrial thickness. Timepoint: 90 Days

Secondary

MeasureTime frame
Improvement in Quality of LifeTimepoint: 90 Days

Countries

India

Contacts

Public ContactProf Neha Pandya

Institute of Teaching and Research in Ayurveda Jamnagar

nehap@itra.edu.in9925650307

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026